Webcast on masitinib in severe asthma on Monday, December 2, 2019
27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis
25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
Positive top-line Phase 3 results for masitinib in severe asthma
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
Financing agreement to pre-finance the 2019 research tax credit
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
Webcast on indolent systemic mastocytosis on November 20, 2019
04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019
Authorization to initiate phase 3 confirmatory study in mastocytosis
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
Update on masitinib programs timelines
10/10/2019 – AB Science provides update on masitinib programs timelines